Historical Stock Chart
2 Months : From Apr 2019 to Jun 2019
By Adria Calatayud
GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) said Thursday that their Trelegy Ellipta inhaler, which treats patients living with uncontrolled asthma, met the primary endpoint in a phase 3 study.
The pharmaceutical companies said the study showed a statistically significant improvement in lung function at 24 weeks of once-daily treatment with Trelegy Ellipta compared with other medication.
However, the drug didn't achieve a statistically significant reduction in the annualized rate of asthma exacerbations, which was the secondary endpoint of the trial, the companies said.
Write to Adria Calatayud at firstname.lastname@example.org
(END) Dow Jones Newswires
May 02, 2019 12:44 ET (16:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.